Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization.

The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications.

Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device.

This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs.

If you’d like to learn more about Hovione and the full session line-up at the 4th Nasal Formulation & Delivery Summit, download our event guide here.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Hanson Wade Group - 4th Nasal Formulation & Delivery Summit. (2026, June 01). Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit. News-Medical. Retrieved on June 01, 2026 from https://www.news-medical.net/news/20260601/Hovione-advances-intranasal-drug-delivery-with-commercial-ready-dry-powder-platform-ahead-of-4th-Nasal-Formulation-Delivery-Summit.aspx.

  • MLA

    Hanson Wade Group - 4th Nasal Formulation & Delivery Summit. "Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit". News-Medical. 01 June 2026. <https://www.news-medical.net/news/20260601/Hovione-advances-intranasal-drug-delivery-with-commercial-ready-dry-powder-platform-ahead-of-4th-Nasal-Formulation-Delivery-Summit.aspx>.

  • Chicago

    Hanson Wade Group - 4th Nasal Formulation & Delivery Summit. "Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit". News-Medical. https://www.news-medical.net/news/20260601/Hovione-advances-intranasal-drug-delivery-with-commercial-ready-dry-powder-platform-ahead-of-4th-Nasal-Formulation-Delivery-Summit.aspx. (accessed June 01, 2026).

  • Harvard

    Hanson Wade Group - 4th Nasal Formulation & Delivery Summit. 2026. Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit. News-Medical, viewed 01 June 2026, https://www.news-medical.net/news/20260601/Hovione-advances-intranasal-drug-delivery-with-commercial-ready-dry-powder-platform-ahead-of-4th-Nasal-Formulation-Delivery-Summit.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.